Financial results for the period ended September 30, 2026
As filed · Gland Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
What happened
FactFinancial results for the period ended September 30, 2026. Unaudited Financial Results (standalone and consolidated) along with Limited Review Report(s). Press Release and Investor Presentation on the financial results of the Company for the above.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Guidance
RevisedThe agreement is expected to provide strong long-term business visibility, with revenue generation anticipated from calendar year 2029.
the revenues will ramp up from '29 because the filings will start happening from next year.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- Technology transfer activities are planned for completion within two years, with revenues expected to commence (management committed by H1 FY27)
- The agreement is expected to provide strong long-term business visibility, with revenue generation anticipated (management committed by FY27)
Evidence
- Gland Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
- Earlier statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +2 corroborating keywords; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%